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Objective: The initial palliative procedure for patients born with hypoplastic left heart
syndrome and related single right ventricle anomalies, the Norwood procedure, re-
mains among the highest risk procedures in congenital heart surgery. The classic Nor-
wood procedure provides pulmonary blood flow with a modified Blalock–Taussig
shunt. Improved outcomes have been reported in a few small, nonrandomized studies
of a modification of the Norwood procedure that uses a right ventricle–pulmonary
artery shunt to provide pulmonary blood flow. Other nonrandomized studies have
shown no differences between the two techniques.
Methods: The Pediatric Heart Network designed a randomized clinical trial to com-
pare outcomes for subjects undergoing a Norwood procedure with either the right ven-
tricle–pulmonary artery or modified Blalock–Taussig shunt. Infants with a diagnosis
of single, morphologically right ventricle anomaly who are undergoing a Norwood
procedure are eligible for inclusion in this study. The primary outcome is death or car-
diac transplant 12 months after random assignment. Secondary outcomes include
postoperative morbidity after Norwood and stage II palliation procedures, right ven-
tricular function and pulmonary arterial growth at stage II palliation, and neurodeve-
lopmental outcomes at 14 months old. Incidence of adverse events will also be
compared between treatment groups.
Conclusion:This studywill make an important contribution to the care of patients with
hypoplastic left heart syndrome and related forms of single, morphologically right
ventricle. It also establishes a model with which other operative interventions for
patients with congenital cardiovascular malformations can be evaluated in the future.
R
efinements in technique, perfusion management, and postoperative care have
improved outcomes for patients born with hypoplastic left heart syndrome
(HLHS) and other single, morphologically right ventricle (RV) conditions
who undergo the Norwood procedure. Nonetheless, patients with these lesions con-
tinue to have a high mortality.1 In the classic Norwood (stage I palliation) procedure,
pulmonary blood flow is provided by a modified Blalock–Taussig shunt (MBTS). A
modification of this procedure involves placing a shunt from the (RV to the PA, rather
than the standard MBTS, to provide pulmonary blood flow.2
Theoretic advantages of the RV-PA shunt are predominantly associated with ab-
sence of diastolic blood flow from the systemic circulation into the pulmonary circu-
lation. They include (1) a more stable postoperative course, (2) increased coronary
arterial flow because of the lack of aortic diastolic runoff, (3) improved weight gain
related to improved splanchnic perfusion, and (4) lower interstage mortality.3-7 Poten-
tial disadvantages of the RV-PA shunt include the following: (1) the ventriculotomy,
which could predispose toward ventricular dysfunction, arrhythmias, and false
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DAbbreviations and Acronyms
APOE 5 apolipoprotein E genotype
CPB 5 cardiopulmonary bypass
HLHS 5 hypoplastic left heart syndrome
MBTS 5 modified Blalock–Taussig shunt
PA 5 pulmonary artery
PHN 5 Pediatric Heart Network
RV 5 right ventricle
aneurysms; (2) free pulmonary insufficiency, resulting in
ventricular dilation, (3) decreased PA growth related to the
lack of forward flow during diastole, and (4) need for earlier
stage II procedure because of hypoxemia.1,5,8-10
No prospective randomized trial has compared patient
outcomes after a Norwood procedure with the MBTS with
those after one incorporating the RV-PA shunt. Several
case series that used historical series of patients with
MBTS as a control group reported improved short-term sur-
vival with the RV-PA shunt.2,4,11,12 In contrast, a retrospec-
tive review comparing contemporaneous results of stage 1
reconstruction with the MBTS versus the RV-PA shunt per-
formed during the same time period showed no differences in
mortality or short-term outcomes.13 A second study also
showed no difference in early morbidity and mortality be-
tween the two shunts, although the patients who underwent
the RV-PA shunt were discharged from the hospital earlier
than were those who underwent the MBTS.9 That same co-
hort was later reported to have no difference in mortality or
morbidity after stage II palliation between MBTS and RV-
PA shunt groups.5 All these studies are confounded by the
fact that the type of shunt placed was determined by surgeon
preference. In addition, the anatomic subtypes differed sig-
nificantly between cohorts. Thus there is a need for a rigorous,
randomized clinical trial to determine the optimal strategy.
The purpose of this report is to describe the design and ratio-
nale of a multisite, randomized clinical trial to compare out-
comes associated with the RV-PA shunt with those of the
MBTS in a prospective and randomized fashion.
Materials and Methods
Study Overview
This trial will test the hypothesis that the RV-PA shunt is associated
with a decrease relative to the MBTS in the frequency of the com-
bined end point of mortality or transplant at 12 months after random
assignment. We plan to enroll 466 infants to be randomly assigned
to undergo either MBTS or RV-PA shunt. The concept for this study
was developed by investigators at the University of Michigan Med-
ical School, the Children’s Hospital of Philadelphia, Children’s
Hospital of Wisconsin, and Children’s Hospital Boston, who collab-
orated with the National Heart, Lung, and Blood Institute–funded
Pediatric Heart Network (PHN)14 to develop the final study design.
The study is being conducted at 14 clinical centers. A flow chart ofThe Journal of Thothe study design is shown in Figure 1. An independent Data and
Safety Monitoring Board and an independent medical monitor
have been established by the National Heart, Lung, and Blood Insti-
tute to monitor this trial for data quality and safety.
Subject Selection
Subject selection criteria were defined to ensure a relatively homo-
geneous group of subjects with a functionally single ventricle lesion
characterized by a single morphologically RV. Inclusion and exclu-
sion criteria are shown in Table 1.
Randomization and Stratification
Subjects are assigned to treatment group with randomly permuted
blocks within strata defined by the presence or absence of aortic atre-
sia and the presence or absence of obstructed pulmonary venous re-
turn.15-18 Obstructed pulmonary venous return is defined by the use
of postnatal intervention, including balloon septostomy, open atrial
septectomy, or urgent Norwood procedure. Aortic atresia is defined
by 2-dimensional and color Doppler echocardiographic findings in-
terpreted at the local center. Because of potential differences in sur-
geon experience and operative techniques, dynamic balancing by
surgeon ensures that treatment arm totals are balanced within each
Newborn with Single RV Anomaly
Screening for Eligibility
Randomization
Norwood with RV-PA ShuntNorwood with MBTS




Anthropometry, Echocardiogram and Catheterization (optional)
Evaluation of 12-month Mortality or Transplantation
14-month Anthropometric, Neurodevelopmental,
Echocardiographic, and Genetics Evaluations (optional),
End of Study
Figure 1. Flow diagram for trial. RV, Right ventricle; MBTS, modi-
fied Blalock–Taussig shunt; PA, pulmonary artery.racic and Cardiovascular Surgery c Volume 136, Number 4 969
Surgery for Congenital Heart Disease Ohye et al
CH
DTABLE 1. Inclusion and exclusion criteria
Inclusion criteria
 Diagnosis of hypoplastic left heart syndrome or related single, morphologically right ventricle anomaly
 Planned Norwood procedure
 Informed consent of parent or legal guardian
Exclusion criteria
 Single, morphologically left ventricle anomaly
 Preoperative identification of anatomic features rendering either modified Blalock–Taussig shunt or right ventricle–pulmonary artery
shunt technically impossible
 Any major congenital abnormality (eg, congenital diaphragmatic hernia, tracheoesophageal fistula) or acquired extracardiac disorder
(eg, meconium aspiration with need for high-frequency ventilation, persistent renal failure requiring dialysis) that investigator
considered could independently affect likelihood of subject meeting primary end pointsurgeon’s case load and will avoid excessively small stratum sizes
that might result from use of more than two stratification factors.
Technical Considerations of Surgery
Each center will strive to maintain a consistent approach to perioper-
ative care and the conduct of the operation, regardless of the shunt
group to which the subject is randomly assigned, for the duration
of the trial. These variables include such techniques as cardiopulmo-
nary bypass (CPB, including the use of regional cerebral perfusion,
hematocrit levels, and methods of pH monitoring) and management
in the intensive care unit before and after surgery. Despite these ef-
forts to standardize the care for the duration of the trial, however,
management techniques invariably change with time. To minimize
the impact of these changes, permuted block randomization will be
used, as mentioned previously. In addition, extensive data on perio-
perative management will be recorded to allow analysis of signifi-
cant changes in management during the trial time frame.
The MBTS and RV-PA shunts are constructed of unvalved poly-
tetrafluoroethylene tube grafts with standard surgical techniques.2,16
Features of cardiac anatomy recognized in the operating room after
random assignment occasionally render the performance of the
MBTS or RV-PA shunt technically infeasible. Although every effort
is made to use the shunt to which the subject has been randomly as-
signed, the surgeon may choose an alternative shunt at any time dur-
ing the operation if it is deemed to be in the subject’s best interest
because of unanticipated anatomic constraints. If the innominate ar-
tery is not appropriate for the MBTS, such as in the scenario of an
aberrant right subclavian artery and inadequate caliber right carotid
artery, the subject will be considered for an aortopulmonary shunt.
Because a shunt arising from the aorta is a shunt from a systemic ar-
tery to the PA, its use will not be considered a treatment crossover.
On rare occasions, if the surgeon considers that the MBTS or an-
other shunt from a systemic artery to the PA cannot be performed,
a crossover will occur. Another possibility is the finding of a large
conal branch on the RV free wall in the area of the proposed origin
of the RV-PA shunt. In this case, the subject will also cross over to
the alternative shunt. It is also possible that after the placement of the
initial randomly assigned shunt, the subject may not be able to be
separated successfully from CPB. The surgeon may place another
type of shunt in an attempt to save the subject’s life.
Study Measurements and Subject Follow-up
Baseline data. Demographic and preoperative data include
pregnancy history, fetal diagnosis, birth weight, race, gender, gesta-970 The Journal of Thoracic and Cardiovascular Surgery c Octtional age, Apgar scores, clinical status and anatomic diagnosis at
presentation, occurrence of important preoperative complications,
age at operation, and genetic evaluation findings (if performed).
All centers perform 2-dimensional echocardiographic studies,
which are reviewed both locally and in the 2-dimensional echocar-
diography core laboratory to evaluate anatomy and ventricular func-
tion. Centers with 3-dimensional echocardiography capability also
collect these studies for local interpretation and review by the 3-
dimensional echocardiography core laboratory. Any additional in-
terventions and important events, as defined by the protocol, are
recorded.
Follow-up visits. The schedule of data collection is summarized
in Table 2. Follow-up data are obtained at five times: (1) during hos-
pitalization for the Norwood procedure, (2) before the stage II pal-
liation, (3) during hospitalization for the stage II palliation, (4) 12
months after random assignment, and (5) at age 14 months. Specific
data and studies include the following:
 echocardiographic and Doppler images obtained for analysis
after the Norwood procedure, before the stage II palliation
and at age 14 months;
 height, weight, and head circumference measured at the time
of each echocardiogram;
 apolipoprotein E genotype (APOE) obtained by buccal swab
from subjects with consent during the hospitalization for the
Norwood procedure (consent for genotyping not required for
participation in the main trial);
 Cardiac catheterization data and images, if a routine cardiac
catheterization is performed for clinical indications before
the stage II palliation;
 Vital status and whether a heart transplant has been per-
formed (collected 12 months after random assignment only).
 The Bayley Scales of Infant Development–II (Harcourt As-
sessment, Inc, San Antonio, Tex), MacArthur-Bates Commu-
nicative Development Inventories (Singular Publishing
Group, San Diego, Calif), Hollingshead Four Factor Scale
(Four-factor index of social status [unpublished manuscript];
Yale University, New Haven, Conn), and Functional Status
II–Revised questionnaire (Albert Einstein College of Medi-
cine, Bronx, NY) at 14 months old.
Echocardiographic data, APOE genotype, and cardiac catheteri-
zation data are centrally interpreted in PHN core laboratories. To
cover long-term follow-up of this unique patient population, the
consent form includes permission to contact each family annually
until the subject reaches the age of 5 years.ober 2008
Ohye et al Surgery for Congenital Heart DiseaseTABLE 2. Schedule of trial measurements
Baseline Follow-up
Measurement Study entry Norwood hosp Discharge Before stage II Stage II hosp Age 12 mo Age 14 mo
Medical history X X X X
Height, weight, and head circumference X X X X
Anatomic subtype X
Intensive care unit and hospital courses X X
Echocardiogram X X X X
Catheterization* X
Apolipoprotein E genotypey X
Death or transplant X
Neurodevelopmental evaluation X
Clinical genetics evaluationy X X
hosp, Hospitalization. *Not mandated by protocol, performed at discretion of attending cardiologist. yNot mandated by protocol, performed only with consent
of family.CH
DTrial Outcomes
The primary outcome is death or cardiac transplant by 12 months af-
ter randomization. Secondary outcomes are listed in Table 3.
Blinding of Treatment Group Assignment
This trial is not blinded with respect to knowledge of treatment as-
signment. Blinding is not feasible for most of the personnel caring
for the subjects, because the treatment strategies produce differences
in physical examination findings and in the follow-up studies per-
formed for the secondary end points, such as echocardiography
and cardiac catheterization. Only the specialists who perform the
neurodevelopmental testing and the APOE genotyping are blinded
to treatment assignment.
Statistical Considerations
For the primary trial result, the proportion of subjects with MBTS
versus RV-PA shunt reaching the primary trial end point by 12
months after randomization will be compared with a Fisher exact
test. Furthermore, to test the hypothesis that differences in the surgi-
cal strategies are present early, a comparison of the primary end
point in the two trial arms will be conducted with the Kaplan–Meier
method for estimation and the Gehan–Wilcoxon test, which places
more weight on early failure times because of weights determined
by risk set sample size. A competing risks analysis (death vs trans-
plant vs stage II surgery performed vs no progression through addi-
tional stages) will also be conducted to characterize subject risk
more fully by treatment group.
All primary analyses will be performed on an intention-to-treat
basis. This approach implies that the rare randomly allocated subject
who receives neither trial shunt (eg, in the event of death between
assignment and the Norwood procedure) would remain classified
in the assigned surgical group for analysis. If it is clear that the de-
cision not to proceed with the Norwood procedure has not been
influenced by knowledge of the assigned shunt, however, then no
bias is incurred, intention-to-treat is preserved, and those subjects
will be excluded from analysis. A review panel will evaluate each
case in which a randomly allocated subject receives neither trial
shunt. If the review panel determines that the decision to use neither
trial shunt was clearly not influenced by treatment assignment (eg,
subject dies before surgery), then that subject will be excludedThe Journal of Thorfrom all analyses. Primary outcome data will be collected for these
subjects so that the impact of the exclusions on primary analysis
results can be assessed.
Secondary analyses will compare treatment groups as follows:
(1) with covariate-adjusted analysis, (2) according to which shunt
was actually in place at the conclusion of the operative procedure,
and (3) after exclusion of any randomly assigned subjects subse-
quently found to have been ineligible for the trial at the time of en-
rollment.
Treatment assignment by prespecified subgroup interaction
analyses are planned to estimate the effects of birth weight, preop-
erative tricuspid regurgitation, type of cerebral perfusion during
stage I palliation, experience of the surgeon, and center volume
(Table 4).
To monitor the trial for large treatment differences, three formal
interim analyses are planned, timed to occur when one quarter, one
half, and three quarters of subjects would be expected to reach the
12-month visit. An O’Brien–Fleming stopping boundary with
a Lan–DeMets adjustment will be used for this purpose. Adverse
event rates by trial arm, as well as death and transplantation rates
in aggregate, are reported to the Data and Safety Monitoring Board
twice a year. To preserve the type I error rate for primary analysis,
death and transplantation rates by treatment arm are reported during
prespecified interim analyses only.
This trial is powered to detect differences in the primary compos-
ite end point (death or cardiac transplant) by 12 months after random
assignment. A review of previous data from the participating centers
for infants born in 2002 and 2003 was performed to calculate an es-
timate of the incidence of death or cardiac transplant for each shunt
under consideration. For subjects undergoing a Norwood procedure
with MBTS at least 1 year earlier, the incidence of death or trans-
plant by 12 months after surgery was 28% (65/236). The expected
mortality for the RV-PA shunt was based on the three member cen-
ters routinely performing the RV-PA shunt exclusively or in a signif-
icant proportion of their Norwood procedures. The data on Norwood
procedures with RV-PA shunts were sparse, and not all patients had
reached 1 year old. Because previously reported data indicate that
events after the stage II procedure are rare,11,19 all deaths and cardiac
transplants, regardless of whether the patient had reached 1 year of
age, were counted. For subjects receiving a RV-PA shunt at the threeacic and Cardiovascular Surgery c Volume 136, Number 4 971
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DTABLE 3. Secondary outcome variables
Morbidity after the Norwood procedure
1. Open sternum (yes or no)
2. Extracorporeal membrane oxygenation (yes or no)
3. Cardiopulmonary resuscitation (yes or no)
4. Time to initial extubation (h)
5. Duration of ventilation (total d)
6. Length of intensive care unit stay (d)
7. Length of hospital stay from day of surgery (d)
Incidence of unintended cardiovascular interventional procedures (composite and individual)
1. Balloon dilation of shunt or branch pulmonary arteries
2. Stent placement in shunt or branch pulmonary arteries
3. Shunt revision
4. Crossover between MBTS and RV-PA shunt
5. Balloon dilation, stent placement, or surgical revision of neoaorta
6. PA reconstructions other than those undertaken as standard component of stage II procedure
Evaluation of RV function by 2-dimensional echocardiography
1. Right ventricular BSA-adjusted Z scores for diastolic and systolic volumes and age-adjusted Z scores for ejection fraction
2. Absolute values for diastolic and systolic volumes and ejection fraction
3. dP/dt obtained from the tricuspid regurgitation jet
4. Severity of tricuspid regurgitation
5. Doppler tissue imaging of RV
a. Systolic annular acceleration and peak velocity
b. Isovolumic myocardial acceleration
Pulmonary arterial growth
1. Angiographic PA cross-sectional area, as determined by the Nakata index
2. Ratio of distal to proximal PA diameter, measured by angiography
3. Incidence of angiographically discrete PA stenosis
4. Change in echocardiographic Nakata index from Norwood procedure to stage II procedure
Stage II perioperative morbidity
1. Cardiopulmonary resuscitation (yes or no)
2. Time to initial extubation (hours)
3. Duration of ventilation (total d)
4. Length of intensive care unit stay (d)
5. Length of hospital stay from day of stage II surgery (d)
Neurodevelopmental outcome
1. Bayley Scales of Infant Development II
2. MacArthur Communicative Developmental Index
3. Functional Status II–Revised questionnaire
MBTS, Modified Blalock–Taussig shunt; RV, right ventricle; PA, pulmonary artery, BSA, body surface area, dP/dt, estimated maximum first derivative of ven-
tricular pressure.centers of interest, the 12-month mortality or transplant rate was as-
sumed to be 16% (14/87). The trial was thus designed to detect
a 12% difference with 85% power at a 2-sided significance level
of .05. After 2% inflation to account for three interim analyses,
this required a total of 466 subjects.
Trial Organization
The PHN Single Ventricle Reconstruction Study Committee and
PHN Steering Committee, together with the National Heart, Lung,
and Blood Institute, are responsible for all aspects of this study.
The protocol has been approved by an independent Protocol Review
Committee and Data and Safety Monitoring Board, and by the insti-
tutional review boards at each clinical center and at the Data Coor-
dinating Center. All centers follow the same protocol and study
procedures.972 The Journal of Thoracic and Cardiovascular Surgery c OctComment
Rationale for Outcome Measures
Infants bornwithHLHS and related conditions have relatively
highmortality, unlike neonates with other forms of congenital
heart disease. The most fundamental research question to an-
swer in a surgical trial in this population, therefore, is whether
the child survives to at least 1 year old, and whether the heart
requires replacement before then. The primary outcome,
death or cardiac transplant by 12 months after random assign-
ment, reflects this clinical imperative. In addition, this defini-
tive end point should facilitate clear interpretation of the trial
results by the medical teams taking care of these patients.
The surgical strategy could affect the postoperative course
after the stage I procedure, as well as perioperative morbidityober 2008
Ohye et al Surgery for Congenital Heart DiseaseTABLE 4. Subgroup factors for estimation of differential treatment effect
 Birth weight ,2500 g vs #2500 g
 Preoperative tricuspid regurgitation proximal jet width ,2.5 mm vs #2.5 mm determined by echocardiography
 Cerebral perfusion during stage I palliation as deep hypothermic circulatory arrest vs regional cerebral perfusion (if subject received both
types of cerebral perfusion during surgery, classification was deep hypothermic circulatory arrest)
 Experience of the surgeon as average number of Norwood procedures performed on randomized subjects per year (as a continuous
variable) and classified as #5, 5-10, 11-15, or .15 procedures/y
 Center volume as average number of Norwood procedures performed on randomized subjects per year (as continuous variable) and
classified as #10, 11-25, 26-40, or .40 procedures/yCH
Dassociated with the stage II procedure. Several standard in-
tensive care unit measures were selected as a basis for
comparing morbidity, because decreasing intensive care
unit morbidity can improve short- and long-term outcomes
and reduce health care costs.20,21
The need for additional procedures implies incomplete
resolution of adverse hemodynamics, carries the risk of fur-
ther morbidity, and may also affect long-term outcome and
health care costs. Several key procedures often used in this
population and that might plausibly differ in frequency be-
tween the trial arms were selected, including crossover
between MBTS and RV-PA shunt, shunt revision, extracor-
poreal membrane oxygenation, diaphragm plication, and pro-
cedures to address stenosis of the shunt, branch pulmonary
arteries, or neoaorta.
Systemic (right) ventricular function can theoretically be
compromised by either shunt. Although myocardial oxygen
delivery and RV function may be optimized when an RV-
PA shunt is used, RV function has not been systematically
evaluated, and the long term effects of the RV ventriculotomy
are unknown. Determining whether the type of shunt placed
at the time of the Norwood procedure affects later RV func-
tion is a crucial component of determining the best surgical
management of infants with HLHS. Establishing baseline
evaluations and standardizing echocardiographic methods
of evaluating RV function will provide early data on a
cohort of subjects who can be followed up serially through
and beyond Fontan palliation to determine whether a
difference in RV function occurs and persists long term,
and whether it eventually contributes to failure of staged
reconstruction.
TheMBTS and RV-PA shunt strategies differ most signif-
icantly in their approach to providing pulmonary arterial
blood flow, which may influence subsequent PA size, rate
of growth, and stenosis. These variables are of clinical signif-
icance in their own right, but they also can affect subsequent
outcome, because small PA size is a known risk factor for pa-
tients undergoing both the stage II palliation and the Fontan
procedure.22-24 The impact of the MBTS relative to the RV-
PA shunt on PA growth and stenosis will be evaluated.
Multiple studies have demonstrated that preschool and
school-aged children with HLHS have neurocognitive andThe Journal of Thobehavioral abnormalities. Risk factors for such abnormalities
include underlying congenital structural central nervous sys-
tem abnormalities, genetic syndromes, disturbed fetal cere-
bral hemodynamics, preoperative seizures, intraoperative
events related to CPB, and such postoperative factors as
low cardiac output syndrome, seizures, and longer of hospital
stay.25-29
It is hypothesized that relative to the MBTS the RV-PA
shunt may reduce neurodevelopmental impairment through
improved postoperative oxygen delivery, less steal from the
systemic circulation through the shunt into the lungs, and
higher diastolic blood pressure. Measures of neurodevelop-
mental status will profile the motor and cognitive capabilities
of study subjects. The effects of knownmodifiers of neurode-
velopment will be evaluated in the analysis. One such mod-
ifier is the APOE*E2 allele, recently found to be associated
with worse neurologic outcome in patients undergoing
CPB.30 APOE genotype will be assessed as a component of
neurodevelopmental outcome.
Limitations
Blinding of subjects and caregivers is desirable in clinical tri-
als because of the potential for bias in medical care and in ad-
judication of treatment outcomes. Practical considerations
preclude blinding in most surgical trials, however, including
this one. In the absence of blinding, it is important to ensure
that random assignment is conducted properly and that end
points are assessed objectively. The PHN’s standard quality
assurance process will be used for close monitoring of
screening and randomization. Although the primary end
point is a composite, most of the events are expected to be
deaths, an objective measure. If a significant number of car-
diac transplants occur, the transplant criteria will be adjudi-
cated independently in each case.
This trial, like many other studies of rare conditions, is
powered to detect a relatively large difference in the primary
end point (16% vs 28%), so a smaller but clinically important
difference might not be detected. Powering the study to de-
tect a smaller difference, however, would require many
more subjects and thus possibly a longer study duration.
The decision to adopt the current design was made to avoid
the loss of equipoise and potential confounding changes inracic and Cardiovascular Surgery c Volume 136, Number 4 973
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Dsurgical techniques and perioperative care that could occur
over a longer time.
To maximize enrollment, the number of secondary out-
come measures is intentionally limited to minimize the num-
ber of extra measurements and thus the burden on subjects
and families. For example, although 48-hour electroenceph-
alographic monitoring or head magnetic resonance imaging
might provide mechanistic data to explain abnormalities in
neurodevelopment, these studies are not included. In addi-
tion, the trial may be underpowered for some of the second-
ary end point analyses.
Importance of Knowledge to Be Gained
Techniques for management of congenital heart lesions
have been adopted solely on the basis of expert consensus
and retrospective analysis, rather than on data from pro-
spective, randomized clinical trials. The primary goal of
the PHN is to promote evidence-based clinical care for chil-
dren and adults with congenital heart disease. This trial of-
fers a unique opportunity for systematic comparison of two
surgical procedures for which equipoise exists among sur-
geons and for determination of the time course of risk
and benefit for each procedure. Not only will the main re-
sults provide an unbiased estimate of relative efficacies of
the two shunts, but standardized information characterizing
the clinical course in a large unselected cohort of infants
with HLHS will be obtained for the first time. The results
of this study will make an important contribution to the
management of the highest-risk group of patients with con-
genital heart disease. Another important contribution of this
trial will be establishment of the basis for long-term follow-
up of a well-characterized cohort of patients with little sys-
tematic information currently available. Finally, this trial
provides a feasible model of collaborative research for the
evaluation of other operative interventions in patients with
congenital cardiovascular malformations.
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